|
Jun 24
|
Alnylam Soars on Positive Heart-Drug Data
|
|
Jun 24
|
Alnylam reveals positive Phase III results for rare heart disease drug vutrisiran
|
|
Jun 24
|
Tech sector growth, EU considers fining Apple: Morning Brief
|
|
Jun 24
|
Alnylam Stock Pops on Surprising Results From a Key Heart Disease Drug
|
|
Jun 24
|
Alnylam Stock Soars on Strong Results in Heart Drug Study
|
|
Jun 24
|
Alnylam stock skyrockets on positive heart drug results
|
|
Jun 24
|
Alnylam Soars After Drug Meets Goal in Heart Disease Trial
|
|
Jun 24
|
Alnylam Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran, Achieving Statistical Significance on Primary and All Secondary Endpoints in Both Overall and Monotherapy Populations
|
|
Jun 24
|
Alnylam (ALNY) Soars 5.3%: Is Further Upside Left in the Stock?
|
|
Jun 24
|
Alnylam says heart drug succeeds in closely watched study
|
|
May 7
|
Alnylam Issues 2023 Corporate Responsibility Report
|
|
May 5
|
The Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) First-Quarter Results Are Out And Analysts Have Published New Forecasts
|
|
May 3
|
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q1 2024 Earnings Call Transcript
|
|
May 3
|
Alnylam (ALNY) Q1 Loss Narrower Than Expected, Sales Rise Y/Y
|
|
May 3
|
Alnylam Pharmaceuticals First Quarter 2024 Earnings: Beats Expectations
|
|
May 3
|
Alnylam Pharmaceuticals Inc (ALNY) (Q1 2024) Earnings Call Transcript Highlights: Strong Growth ...
|
|
May 3
|
Decoding Alnylam Pharmaceuticals Inc (ALNY): A Strategic SWOT Insight
|
|
May 2
|
Compared to Estimates, Alnylam (ALNY) Q1 Earnings: A Look at Key Metrics
|
|
May 2
|
Alnylam Pharmaceuticals (ALNY) Reports Q1 Loss, Tops Revenue Estimates
|
|
May 2
|
Alnylam Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Period Activity
|